Recently celebrating her six-month birthday, Emma has been enduring a rare and severe genetic skin disorder known as dystrophic epidermolysis bullosa, which makes her skin extremely fragile and susceptible to blistering upon contact. As her condition progresses, Emma has been receiving a groundbreaking gene therapy that hastens wound healing and alleviates her agonizing pain. However, the cost of this treatment is exorbitant, amounting to 242,000 euros, of which 100,000 euros has been secured through donations to the Children's Fund, leaving a gap of 142,000 euros yet to be filled for her continued care.

Dystrophic epidermolysis bullosa is known as the most severe form of this genetic condition, impacting not only the skin but also the mucous membranes throughout Emma's body. Each minor touch can lead to blisters, which have the potential to burst and turn into painful wounds requiring daily care and bandaging. With advancements in treatment, the Vyjuvek gene therapy has emerged as a beacon of hope, enabling Emma's wounds to heal more rapidly, thus improving her quality of life significantly compared to just a few years ago when no treatments were available for her condition.

The need for substantial financial support illustrates the challenges faced by families dealing with rare genetic disorders and emphasizes the importance of community aid and resources for such critical healthcare needs. As Emma's family seeks the remaining funds, it highlights a pressing need for awareness and support for rare diseases, calling on both the public and private sectors to contribute to the welfare of children like Emma who are in dire need of medical assistance to manage their conditions effectively.